Shopping Cart
- Remove All
Your shopping cart is currently empty
ALK/HDAC-IN-1 is a dual inhibitor that targets both ALK and HDAC6, demonstrating IC50 values of 16 nM and 1.03 μM, respectively. This compound exhibits anti-tumor activity.

| Description | ALK/HDAC-IN-1 is a dual inhibitor that targets both ALK and HDAC6, demonstrating IC50 values of 16 nM and 1.03 μM, respectively. This compound exhibits anti-tumor activity. |
| Targets&IC50 | HDAC6:1.03 μM, HDAC11:16.6 μM, HDAC8:1.69 μM, HDAC1:10.8 μM |
| In vitro | ALK/HDAC-IN-1 inhibits the proliferation of cancer cells A549, HepG2, MCF7, U87MG, and H2228 with IC50 values of 0.33, 0.59, 0.55, 0.62, and 0.44 μM, respectively. Additionally, ALK/HDAC-IN-1 inhibits the CYP450 enzyme CYP2C9, with an IC50 of 2.65 μM. |
| In vivo | ALK/HDAC-IN-1, administered at doses ranging from 0 to 20 mg/kg via intraperitoneal injection for 21 days, effectively suppresses tumor growth in A549 xenografts in BALB/c mice, with no significant toxicity observed. |
| Formula | C27H31N5O4 |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |

Copyright © 2015-2025 TargetMol Chemicals Inc. All Rights Reserved.